HD, H., P, K., C, G., R, S., B, D., M, C., . . . RC, B. (2021). Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. Immunotherapy, 13(2), 125. https://doi.org/10.2217/imt-2020-0256
Chicago Style (17th ed.) CitationHD, Hummel, et al. "Pasotuxizumab, a BiTE® Immune Therapy for Castration-resistant Prostate Cancer: Phase I, Dose-escalation Study Findings." Immunotherapy 13, no. 2 (2021): 125. https://doi.org/10.2217/imt-2020-0256.
MLA (9th ed.) CitationHD, Hummel, et al. "Pasotuxizumab, a BiTE® Immune Therapy for Castration-resistant Prostate Cancer: Phase I, Dose-escalation Study Findings." Immunotherapy, vol. 13, no. 2, 2021, p. 125, https://doi.org/10.2217/imt-2020-0256.
Warning: These citations may not always be 100% accurate.
